Recent national trends in outcomes and economic disparities among adult sickle cell disease-related admissions.
Admission trends
Economic disparities
Inpatient mortality
Sickle cell disease
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
31
01
2023
accepted:
26
07
2023
medline:
11
9
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
Sickle cell disease (SCD) is an inherited disorder caused secondary to a mutation in the hemoglobin beta subunit. There is sparse information regarding the trends in outcomes of SCD admissions in the past decade where rapid advances have been made in treatment. In this study, we wanted to analyze the trends and outcomes of SCD admissions in the United States from 2011 to 2019 and the influence of socio-economic status. Data were obtained from the National Inpatient Sample (NIS) database using the International Classification of Disease (ICD-9) and ICD-10 codes. Trends for primary in-hospital outcomes including mortality, length of stay (LOS), and total hospitalization charges (THC) were assessed. The impact of economic status on these outcomes was also studied. There was an annual percent change (APC) in the number of admissions for SCD of + 2.5% from 2010 to 2015 (95% CI: 1.3-3.8%, p = 0.003). However, there was no significant change in the number of admissions between 2015 and 2019 (95% CI - 1.8-0.7%, p = 0.323). The overall mortality across the years has decreased by about 4% yearly at the population level (p = 0.008, 95% CI 2-8%). However, the inpatient mortality for the high-income group had decreased significantly from 2010 to 2019, whereas there was no difference in the mortality rate for the low-income group across the decade. Despite the advances in the understanding of SCD and its treatment, its benefits have not reached all the people affected. Meaningful progress in healthcare is not achievable unless these economic disparities are addressed. Economic policies to address these inequities are the need of the hour.
Identifiants
pubmed: 37522971
doi: 10.1007/s00277-023-05388-y
pii: 10.1007/s00277-023-05388-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2659-2669Informations de copyright
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Rees DC, Williams TN, Gladwin MT (2010) Sickle-cell disease. Lancet 376(9757):2018–2031. https://doi.org/10.1016/S0140-6736(10)61029-X
doi: 10.1016/S0140-6736(10)61029-X
pubmed: 21131035
Piel FB, Steinberg MH, Rees DC (2017) Sickle cell disease. N Engl J Med 376(16):1561–1573. https://doi.org/10.1056/NEJMra1510865
doi: 10.1056/NEJMra1510865
pubmed: 28423290
Lanzkron S, Strouse JJ, Wilson R et al (2008) Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 148(12):939–955. https://doi.org/10.7326/0003-4819-148-12-200806170-00221
doi: 10.7326/0003-4819-148-12-200806170-00221
pubmed: 18458272
pmcid: 3256736
Josephson CD, Su LL, Hillyer KL, Hillyer CD (2007) Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfus Med Rev 21(2):118–133. https://doi.org/10.1016/j.tmrv.2006.11.003
doi: 10.1016/j.tmrv.2006.11.003
pubmed: 17397762
Carden MA, Little J (2019) Emerging disease-modifying therapies for sickle cell disease. Haematologica 104(9):1710–1719. https://doi.org/10.3324/haematol.2018.207357
doi: 10.3324/haematol.2018.207357
pubmed: 31413089
pmcid: 6717563
Yawn BP, Buchanan GR, Afenyi-Annan AN et al (2014) Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members [published correction appears in JAMA. 2014 Nov 12;312(18):1932] [published correction appears in JAMA. 2015 Feb 17;313(7):729]. JAMA 312(10):1033–1048. https://doi.org/10.1001/jama.2014.10517
doi: 10.1001/jama.2014.10517
pubmed: 25203083
Kanter J, Smith WR, Desai PC, Treadwell M, Andemariam B, Little J, Nugent D, Claster S, Manwani DG, Baker J, Strouse JJ, Osunkwo I, Stewart RW, King A, Shook LM, Roberts JD (2020) Sophie Lanzkron; Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Adv 4(16):3804–3813. https://doi.org/10.1182/bloodadvances.2020001743
doi: 10.1182/bloodadvances.2020001743
pubmed: 32785684
pmcid: 7448595
Payne AB, Mehal JM, Chapman C, Haberling DL, Richardson LC, Bean CJ, Hooper WC (2020) Trends in sickle cell disease–related mortality in the United States, 1979 to 2017. Ann Emerg Med 76(3):S28–S36
doi: 10.1016/j.annemergmed.2020.08.009
pubmed: 32928459
Hamideh D, Alvarez O (2013) Sickle cell disease related mortality in the United States (1999–2009). Pediatr. blood & cancer 60(9):1482–1486
doi: 10.1002/pbc.24557
Cost H, Project U Introduction to the HCUP National Inpatient Sample (NIS). The national (nationwide) inpatient sample database documentation. Rockville. AHRQ Available at: https://www.hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2018.jsp
Houchens RL, Ross DN, Elixhauser A, Jiang J (2014) HCUP NIS Related Reports ONLINE. In: Nationwide inpatient sample redesign final report. Agency for Healthcare Research and Quality. http://www.hcupus.ahrq.gov/db/nation/nis/nisrelatedreports.jsp
Elixhauser A, Heslin KC, Owens PL (2017) U.S. Agency for Healthcare Research and Quality. In: Healthcare cost and utilization project (HCUP) Recommendations for reporting trends using ICD-9-CM and ICD-10-CM/PCS data. https://www.hcupus.ahrq.gov/datainnovations/icd10_resources.jsp
Cowen ME, Dusseau DJ, Toth BG, Guisinger C, Zodet MW, Shyr Y (1998) Casemix adjustment of managed care claims data using the clinical classification for health policy research method. Med. Care 36(7):1108–1113. https://doi.org/10.1097/00005650-199807000-00016
doi: 10.1097/00005650-199807000-00016
pubmed: 9674627
Shaka H, Edigin E (2021) A revised comorbidity model for administrative databases using clinical classifications software refined variables. Cureus 13(12)
HCUP Clinical classifications software refined (CCSR) for ICD-10-PCS procedures, v2021.1. Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality, Rockville Available at: http://www.hcup-us.ahrq.gov/toolssoftware/ccsr/prccsr.jsp .
Sundararajan V, Quan H, Halfon P et al (2007) Cross-national comparative performance of three versions of the ICD-10 Charlson index. Med. Care 45:1210–1215
doi: 10.1097/MLR.0b013e3181484347
pubmed: 18007172
Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates [published correction appears in Stat Med 2001 Feb 28;20(4):655]. Stat Med 19(3):335–351. https://doi.org/10.1002/(sici)1097-0258(20000215)19
doi: 10.1002/(sici)1097-0258(20000215)19
pubmed: 10649300
Zoorob RJ, Salemi JL, Mejia de Grubb MC, Modak S, Levine RS (2019) A nationwide study of breast cancer, depression, and multimorbidity among hospitalized women and men in the United States. Breast Cancer Res Treat 174(1):237–248. https://doi.org/10.1007/s10549-018-5059-5
doi: 10.1007/s10549-018-5059-5
pubmed: 30465155
Ikedionwu CA, Dongarwar D, Williams C et al (2021) Trends and risk factors for leishmaniasis among reproductive aged women in the United States. Int J MCH AIDS 10(2):166–173. https://doi.org/10.21106/ijma.478
doi: 10.21106/ijma.478
pubmed: 34386298
pmcid: 8346677
Laswi H, Attar B, Kwei R, Ojemolon P, Ebhohon E, Shaka H (2022) Trends of alcohol withdrawal delirium in the last decade: analysis of the nationwide inpatient sample. Gastroenterology Res 15(4):207–216. https://doi.org/10.14740/gr1550
doi: 10.14740/gr1550
pubmed: 36129415
pmcid: 9451584
Dunn A, Grosse SD, Zuvekas SH (2018) Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv Res 53:175–196
doi: 10.1111/1475-6773.12612
pubmed: 27873305
Okam MM, Shaykevich S, Ebert BL, Zaslavsky AM, Ayanian JZ (2014) National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008. Med Care 52(7):612–618. https://doi.org/10.1097/MLR.0000000000000143
doi: 10.1097/MLR.0000000000000143
pubmed: 24926708
pmcid: 4177169
Voskaridou E, Christoulas D, Bilalis A et al (2010) The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 115(12):2354–2363. https://doi.org/10.1182/blood-2009-05-221333
doi: 10.1182/blood-2009-05-221333
pubmed: 19903897
Ferster A, Tahriri P, Vermylen C et al (2001) Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 97(11):3628–3632. https://doi.org/10.1182/blood.v97.11.3628
doi: 10.1182/blood.v97.11.3628
pubmed: 11369660
Badawy SM, Thompson AA, Lai JS, Penedo FJ, Rychlik K, Liem RI (2017) Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatr. Blood Cancer 64(6). https://doi.org/10.1002/pbc.26369
Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R (2011) Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am. J. Hematol 86(3):273–277. https://doi.org/10.1002/ajh.21968
doi: 10.1002/ajh.21968
pubmed: 21328441
Raphael JL, Dietrich CL, Whitmire D, Mahoney DH, Mueller BU, Giardino AP (2009) Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatric blood & cancer 52(2):263–267. https://doi.org/10.1002/pbc.21781
doi: 10.1002/pbc.21781
Charache S, Terrin ML, Moore RD et al (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332(20):1317–1322. https://doi.org/10.1056/NEJM199505183322001
doi: 10.1056/NEJM199505183322001
pubmed: 7715639
Ballas SK, Barton FB, Waclawiw MA et al (2006) Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes 4:59. Published 2006 Aug 31. https://doi.org/10.1186/1477-7525-4-59
doi: 10.1186/1477-7525-4-59
pubmed: 16942629
pmcid: 1569824
Steinberg MH, Barton F, Castro O et al (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment [published correction appears in JAMA. 2003 Aug 13;290(6):756]. JAMA 289(13):1645–1651. https://doi.org/10.1001/jama.289.13.1645
doi: 10.1001/jama.289.13.1645
pubmed: 12672732
Verma HK, Lakkakula S, Lakkakula BV (2018) Retrospection of the effect of hydroxyurea treatment in patients with sickle cell disease. Acta Haematol. Pol 49(1):1–8
doi: 10.2478/ahp-2018-0001
Tang AY, Zhou M, Maillis AN, Lai KW, Lane PA, Snyder AB (2023) Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019. Pediatr Blood Cancer 70(3):e30152. https://doi.org/10.1002/pbc.30152
doi: 10.1002/pbc.30152
pubmed: 36579749
Drasar E, Igbineweka N, Vasavda N et al (2011) Blood transfusion usage among adults with sickle cell disease - a single institution experience over ten years. Br J Haematol. 152(6):766–770. https://doi.org/10.1111/j.1365-2141.2010.08451.x
doi: 10.1111/j.1365-2141.2010.08451.x
pubmed: 21275951
Lee L, Smith-Whitley K, Banks S, Puckrein G (2019) Reducing health care disparities in sickle cell disease: a review. Public Health Rep 134(6):599–607. https://doi.org/10.1177/0033354919881438
doi: 10.1177/0033354919881438
pubmed: 31600481
pmcid: 6832089